Insurance plans could have to cover autoimmune drugs

In Washington, a House health proposal would require insurance plans to cover drugs used to treat autoimmune diseases and certain blood disorders. For patients, that matters where insurance is least abstract, at the pharmacy counter, where coverage rules turn into monthly bills and refill decisions.

The measure comes from Rep. Julie Johnson, a Texas Democrat, with Rep. Mike Lawler, a New York Republican, as cosponsor. It would touch three federal law tracks that shape health coverage: the Employee Retirement Income Security Act of 1974, known as ERISA, the Public Health Service Act and the Internal Revenue Code of 1986.

At the pharmacy counter

The practical change is straightforward. If a doctor prescribes a drug for one of the covered conditions, the plan would have to treat that medicine as a required benefit instead of leaving patients to argue over coverage case by case.

Autoimmune diseases can make the body attack its own tissues. Blood disorders can interfere with clotting, oxygen flow or blood-cell production. Those are conditions where treatment can stretch on for years, and any coverage gap can echo through a household budget.

Why three lawbooks matter

ERISA governs many employer plans, the Public Health Service Act reaches individual-market coverage and the tax code ties into some tax-linked insurance rules. Writing the same standard into all three places matters because families move between coverage types, and a rule that lives in only one bucket can leave gaps elsewhere.

That broader reach is what gives the bill its weight. It does not redraw the entire health system, but it would push the same coverage requirement across more than one part of it, instead of letting patients’ access depend on which kind of plan they have.